In a Phase I trial in patient with chronic lymphocytic leukemia (CLL) and NHL, treatment with CG-806 resulted in decreased phosphorylation of SYK and BTK in the circulating malignant cells within 8 h of administration [14]. Here, SYK is linked to non-Hodgkin lymphoma.